Synergism of a novel MCL‑1 downregulator, acriflavine, with navitoclax (ABT‑263) in triple‑negative breast cancer, lung adenocarcinoma and glioblastoma multiforme.

导出 OA

翻译打印收藏纠错

第一作者： Anbok,Lee

第一单位： Department of Surgery, Busan Paik Hospital, College of Medicine, Inje University, Busan 47392, Republic of Korea.

作者： Anbok,Lee ^[1] ; Hyeon-Ok,Jin ^[2] ; Md,Masudul Haque ^[3] ; Hee Yeon,Kim ^[1] ; Hana,Jung ^[3] ; Jin Hee,Park ^[3] ; Ilwhan,Kim ^[4] ; Joo Yeon,Song ^[5] ; Hye Kyoung,Yoon ^[6] ; Hyoung Kyu,Kim ^[7] ; Jin,Han ^[7] ; In-Chul,Park ^[8] ; Kwang Seok,Kim ^[8] ; Sae Gwang,Park ^[3]

作者单位： Department of Surgery, Busan Paik Hospital, College of Medicine, Inje University, Busan 47392, Republic of Korea. ^[1] KIRAMS Radiation Biobank, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea. ^[2] Department of Microbiology and Immunology, College of Medicine, Inje University, Busan 47392, Republic of Korea. ^[3] Department of Internal Medicine, Division of Oncology, Haeundae Paik Hospital, College of Medicine, Inje University, Busan 48108, Republic of Korea. ^[4] Department of Pathology, Dongnam Institute of Radiological and Medical Sciences, Busan 46033, Republic of Korea. ^[5] Department of Pathology, Inje University, Busan 47392, Republic of Korea. ^[6] Cardiovascular and Metabolic Disease Center, Smart Marine Therapeutic Center, College of Medicine, Inje University, Busan 47397, Republic of Korea. ^[7] Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea. ^[8]

关键词 acriflavine drug resistance myeloid cell leukemia sequence?1 downregulation navitoclax triple?negative breast cancer